Our relatively small cohort suggested that poor ECOG PS, a KRAS-mutated tumor, and elevated levels of serum LDH, WBC, and ALP are associated with poorer survival outcomes upon trifluridine/tipiracil treatment. The gene discussed is KRAS; the disease is neoplasm.